Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new study led by the University of Oxford on over 90,000 participants shows that there is no upper threshold to the benefits of exercise in reducing the risk of cardiovascular disease – ‘every move counts towards better cardiovascular health.’

Runner

Cardiovascular disease is the leading cause of death globally, claiming around 17.9 million lives each year. Until now, it has been difficult to quantify the protective effect of physical activity, since previous studies have typically measured this using questionnaires. These methods are crude, subject to poor recall and cannot accurately record all activity that takes place throughout the day. This has made it difficult to assess whether increasing physical activity always gives an additional benefit in reducing the risk of cardiovascular disease, or if there is an upper limit on improvements to cardiovascular health from exercise.

A new, large-cohort study led by the University of Oxford has resolved this by using accelerometers (wrist-worn devices) to accurately record the activity of over 90,000 participants followed over five years. This found that physical activity is not only associated with lower risk of developing cardiovascular disease, but the greatest benefit is seen for those who are active at the highest level.

The full story is available on the University of Oxford website

Similar stories

New form of gift wrap drives male reproductive success

General Research

A study from the Department of Physiology, Anatomy and Genetics (DPAG) has identified a new communication mechanism that ensures the transfer of a complex mix of signals and nutrients required for successful reproduction between males and females.

PRINCIPLE trial finds antibiotics azithromycin and doxycycline not generally effective treatments for COVID-19

Coronavirus COVID-19 General Research

In March 2020, the UK-wide Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE) trial was established as a flexible, platform randomised clinical trial to test a range of potential treatments for COVID-19 that might be suitable for use in the community to help people recover more quickly and prevent the need for hospital admission. The trial is one of three national platform trials for COVID-19 treatments, and complements the RECOVERY and REMAP-CAP trials that focus on hospitalised patients.

Early animal studies yield promising results for new potential COVID-19 vaccine

Coronavirus COVID-19 General Research

Studies carried out in the MRC Human Immunology Unit (MRC HIU) in collaboration with the Pirbright Institute have shown that a new potential vaccine against COVID-19, named RBD-SpyVLP, produces a strong antibody response in mice and pigs, providing vital information for the further development of the vaccine. Although this type of vaccine is not a competitor for the first wave of vaccines, it is hoped that it will be useful as a standalone vaccine or as a booster for individuals primed with a different COVID-19 vaccine.

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.